Review and meta-analysis of biosimilars for the treatment of rheumatoid arthritis

Biosimilars/Research | Posted 04/06/2021 post-comment0 Post your comment

Authors from Japan provide a new perspective on biosimilars for management of rheumatoid arthritis (RA) to provide evidence of efficacy and safety of biosimilars compared with reference biological disease-modifying anti-rheumatic drugs (bDMARDs) (reference bDMARDs) in patients with RA as a part of the process of developing the 2020 update of the Japan College of Rheumatology (JCR) guidelines for the management of RA [1].

20 AA010933

Increasing costs for treating RA, including expensive bDMARDs, have become an important issue not only for patients but also for societies. The cost of biosimilars is approximately 60% that of the reference bDMARDs. Therefore, the widespread use of biosimilars can be expected to be more cost-effective and useful considering the reduction of the economic burden for society and the patient.

The systematic review carried out by Tanaka et al. included 20 randomized controlled trials using biosimilars of infliximab, etanercept and adalimumab. A meta-analysis revealed that the risk ratios (RRs) and 95% confidence intervals (CIs) of achieving the American College of Rheumatology 50% response (ACR50) at Week 24 and serious adverse events (SAEs) for biosimilars compared with the reference bDMARDs were 1.04 (0.98–1.10) and 0.84 (0.61–1.18), respectively. The RRs of achieving ACR50 and SAEs at Week 24 were respectively 0.93 (0.69–1.26) and 2.15 (0.55–8.35) in the patients who switched to biosimilars from the reference bDMARDs and 0.92 (0.76–1.12) and 1.41 (0.32–6.15) in those who continued the reference bDMARDs.

The results indicated that both biosimilars and reference bDMARDs were equally useful for patients with RA. Introduction of biosimilars had equivalent efficacy and safety to reference bDMARDs in RA patients with high or moderate disease activity who had insufficient responses to conventional synthetic (cs)DMARDs (traditional drugs, such as methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, gold salts). In addition, switching to biosimilars was equally useful in RA patients treated with reference bDMARDs compared to maintaining bDMARDs (continuing reference bDMARDs or continuing biosimilars).

The authors noted that there is no Cochrane review on biosimilars in patients with RA. Therefore, they concluded that this study is the first comprehensive meta-analysis investigating whether biosimilars can be used in the same way as reference bDMARDs in patients with active RA who are refractory to treatment with csDMARDs.

Conflict of interest
The authors of the research paper [1] reported conflict of interest, including having received lecture fees, consulting fees, research grants, speaker fees and honoraria from pharmaceutical companies. For full details of the authors’ conflict of interest, see the research paper [1].

Abstracted by Dr Eiichi Tanaka, Associate Professor, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine and Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan.

Editor’s comment
Readers interested to learn more about biosimilars in Japan are invited to visit www.gabi-journal.net to view the following manuscripts published in GaBI Journal:

Biosimilar development and regulation in Japan

Japan proving to be a favourable market for biosimilars

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.4 – CiteScoreTracker 2021 (Last updated on 5 May 2021)

Submit a manuscript to GaBI Journal

Related articles
Naming and interchangeability for biosimilars in Japan

Biosimilars approved in Japan

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Reference
1. Tanaka E, Kawahito Y, Kohno M, et al. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2021 Apr 6:1-13.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Clinical development of biosimilars in the oncology setting
Cancer image015
Biosimilars/Research Posted 17/09/2021
Knowledge and perceptions of naming for biosimilars in the US
Naming 1 V13I27
Biosimilars/Research Posted 10/09/2021
New quality-range-setting method for biosimilarity assessment
127 AA010925
Biosimilars/Research Posted 10/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010